Highly Efficient Directed Differentiation of Human Induced Pluripotent Stem Cells into Cardiomyocytes
Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a novel source of cells for patient-specific cardiotoxicity drug testing, drug discovery, disease modeling, and regenerative medicine. We describe a versatile and cost-effective protocol for in vitro cardiac differentiation that is effective for a wide variety of hiPSC and human embryonic stem cell (hESC) lines. This highly optimized protocol produces contracting human embryoid bodies (hEB) with a near total efficiency of 94.7 � 2.4% in less than 9 days, and minimizes the variability in cardiac differentiation commonly observed between various hiPSC and hESC lines. The contracting hEB derived using these methods contain high percentages of pure functional cardiomyocytes, highly reproducible electrophysiological profiles, and pharmacologic responsiveness to known cardioactive drugs.
- Aseptic Technique and Good Cell Culture Practice
- Monoclonal Antibodies Specific for Leukocyte Adhesion Molecules: Selective Protocols of Immunization and Screening Assays for Ge
- Isolation and Culture of Human Colon Epithelial Cells Using a Modified Explant Technique Employing a Noninjurious Approach
- Circulating Endothelial Progenitor Cells (CEPC)
- Cell-free System for the examination of apoptotic activity in cytoplasmic extracts
- Hepatic Maturation of hES Cells by Using a Murine Mesenchymal Cell Line Derived from Fetal Livers
- Time-Lapse Imaging of Necrosis
- In Vivo and In Vitro Tools to Identify and Study Transcriptional Regulation of USF-1 Target Genes
- 血清热灭活您是否在浪费时间?
- A rapid, quantitative and inexpensive method for detecting apoptosis by flow cytometry in transiently transfected cells